Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial.
PMID: 29608685
2018
The Journal of antimicrobial chemotherapy
Abstract: Three patients (none previously exposed to integrase inhibitors) prematurely discontinued treatment due to viral failure: dolutegravir/lamivudine (n = 1), no resistance mutations (subject A); dolutegravir (n = 2), N155H, S147G and Q148R resistance mutations (subject B), and E138K, G140S and N155H resistance mutations (subject C).
HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy.
PMID: 29617822
2018
The Journal of infectious diseases
Abstract: INSTI-RAMs (S230R, R263K, N155H, and E92Q+N155H) were detected in 4 patients, no INSTI-RAMs were detected in 4 patients, and sequencing of the integrase gene was unsuccessful in 2 patients.
Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing.
PMID: 29873733
2018
The Journal of antimicrobial chemotherapy
Abstract: Among 53 patients harbouring at least one resistance mutation detected by both techniques, the most dominant INSTI resistance mutations were N155H (45%), Q148H/K/R (23%), T97A (19%) and Y143C (11%).
Rapid Development of High-Level Resistance to Dolutegravir With Emergence of T97A Mutation in 2 Treatment-Experienced Individuals With Baseline Partial Sensitivity to Dolutegravir.
PMID: 30568974
2018
Open forum infectious diseases
Discussion: In these cases, genotypic analysis revealed that T97A emerged in addition to other mutations, including E92E/Q, E138E/K, and N155H.
Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial.
Result: One participant had predicted intermediate-level (mutations T97A+R263K) and two predicted high-level (N155H, T97A+Y143R/C) raltegravir resistance mutations (0.6% of those randomised, accounting for missing genotypes using probability weights).
Prevalence of Integrase Strand Transfer Inhibitors Resistance Mutations in Integrase Strand Transfer Inhibitors-Naive and -Experienced HIV-1 Infected Patients: A Single Center Experience.
PMID: 29631420
2018
AIDS research and human retroviruses
Abstract: Among them, 10 harbored N155H, 4 Q148H, 2 Q148R, 2 Y143C/S, and 2 T66A/I/T, respectively.
Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
Introduction: In addition, treatment failure in such individuals was associated with the presence of various RAL/EVG resistance substitutions that predated DTG use, most notably at positions Q148 and N155H.
Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.
PMID: 28369593
2017
The Journal of antimicrobial chemotherapy
Abstract: After >6 months on dolutegravir therapy, three patients with baseline N155H experienced viral rebound.
Abstract: For raltegravir-experienced individuals, the resistance mutation profile in 9 of 10 viraemic patients was as follows: N155H + A153G/S (four); Y143G + A153S (two); Q148R + G140A/S (two); and Y143C + Q91R (one).
Abstract: In two of them N155H was replaced by Q148K/R and in another by G118R.
Abstract: Of note, all patients with Y143G and N155H devel
Temporal Patterns and Drug Resistance in CSF Viral Escape Among ART-Experienced HIV-1 Infected Adults.
PMID: 28328546
2017
Journal of acquired immune deficiency syndromes (1999)
Result: Two studies reported sequencing the integrase gene in CSF; N155H, L74I, and Q148R mutations were observed as single mutations in the integrase gene, and Y143C was observed in combination with T66I.
Discussion: Three CSF integrase mutations were identified in CSF (N155H, Y143C, and Q148R).
HIV mutation literature information.
PMID: 
2018
The Journal of antimicrobial chemotherapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT